Effects of Dupilumab on Itch-Related Events in Atopic Dermatitis: Implications for Assessing Treatment Efficacy in Clinical Practice

Cells. 2023 Jan 5;12(2):239. doi: 10.3390/cells12020239.

Abstract

Dupilumab attenuates itch and skin inflammation in patients with atopic dermatitis (AD). However, itch-related events that are improved by dupilumab remain unclear. Therefore, the present study investigated changes in clinical scores, serum biomarkers, and the number of intraepidermal nerve fibers (IENFs) using skin biopsies and blood samples from 12 patients with moderate to severe AD before and after treatment with dupilumab. Clinical manifestations were assessed using eczema area and severity index (EASI) and visual analogue scale (VAS) scores at baseline and after 8 and 16 weeks of treatment. Serum levels of total immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), interleukin (IL)-4, IL-13, IL-22, and IL-31 were examined by electrochemiluminescence, chemiluminescent enzyme immunoassays, ProQuantum immunoassays, and enzyme-linked immunosorbent assays (ELISA) at baseline and after 8 and 16 weeks of treatment. In skin biopsies from AD patients at baseline and after 16 weeks of treatment, IENFs were examined immunohistochemically with the anti-protein gene product (PGP) 9.5 antibody. The dupilumab treatment significantly improved EASI and VAS scores and decreased serum levels of TARC, IgE, and IL-22, whereas those of IL-13 and IL-31, and the number of IENFs remained unchanged and those of IL-4 increased. VAS scores were positively correlated with serum TARC, IL-22, and IgE levels and the degree of epidermal thickening. Serum IL-31 levels were positively correlated with the number of IENFs. These results suggest that serum TARC, IL-22, and IgE levels and epidermal thickness are itch-related events associated with dupilumab treatment and that serum IL-31 levels may reflect the degree of IENF density in AD patients. Therefore, dynamic changes may be used to assess the efficacy of dupilumab treatment to treat itching and inflammation in patients with AD.

Keywords: atopic dermatitis; dupilumab; epidermal thickness; intraepidermal nerve fibers; serum biomarkers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dermatitis, Atopic* / complications
  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Immunoglobulin E
  • Inflammation
  • Interleukin-13
  • Pruritus / drug therapy
  • Treatment Outcome

Substances

  • dupilumab
  • Interleukin-13
  • Immunoglobulin E

Grants and funding

This work was partly supported by a Grant-in-Aid for Scientific Research (B) [Grant numbers 20H03568 and 22H02956] and a Grant-in-Aid for Early-Career Scientists (Grand number 19K17817 and 21K16307).